Literature DB >> 9299855

The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients.

P Prandoni1, S Villalta, P Bagatella, L Rossi, A Marchiori, A Piccioli, E Bernardi, B Girolami, P Simioni, A Girolami.   

Abstract

BACKGROUND AND
OBJECTIVE: In contrast to the extensive documentation on the short-term outcome of patients with acute deep vein thrombosis (DVT) of the lower extremities, little is known about the long-term clinical course of this disease. To determine the clinical course of patients with a first episode of symptomatic DVTn over an 8-year follow-up period. The primary aims were to assess the long-term incidence of recurrent venous thromboembolism and that of the post-thrombotic syndrome. In addition, we determined mortality and evaluated potential risk factors for all these outcomes.
METHODS: This was designed as a prospective cohort follow-up study. Consecutive symptomatic outpatients with a first episode of venography proven DVT were treated with an initial course of full-dose (low molecular weight) heparin, followed by at least three months of oral anticoagulants. After discharge, they were instructed to wear compression elastic stockings for at least two years. Follow-up assessments were scheduled at three and six months, and then every six months up to eight years. Diagnosis of recurrent venous thromboembolism was made according to standard criteria. The presence of post-thrombotic syndrome was evaluated using a standardized scale.
RESULTS: A total of 528 consecutive patients with a first episode of venography confirmed DVT were included in the study. The cumulative incidence of recurrent venous thromboembolism after two, five and eight years was 17.2, 24.3 and 29.7%, respectively. Malignancy and impaired coagulation inhibition increased the risk of recurrent venous thromboembolism (RR = 1.48 and 2.0, respectively). In contrast, surgery and recent trauma or fracture were associated with a diminished risk of recurrent venous thromboembolism (RR = 0.65 and 0.39, respectively). The cumulative incidence of post-thrombotic syndrome after two, five and eight years was 24.5, 29.6 and 29.8%, respectively. The development of ipsilateral recurrent DVT was strongly associated with the risk for post-thrombotic syndrome (risk ratio, 2.4). Survival after eight years was 69%. The presence of malignancy increased the risk of death remarkably (risk ratio, 7.1). INTERPRETATION AND
CONCLUSIONS: Symptomatic DVT carries a high risk for recurrent venous thromboembolism that persists for many years, especially in patients without transient risk factors for DVT. The post-thrombotic syndrome occurs in almost one-third of patients and is strongly related to recurrent ipsilateral DVT. Our findings challenge the widely adopted short course of anticoagulation in patients with symptomatic DVT.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9299855

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  50 in total

Review 1.  Anticoagulation in patients with thromboembolic disease.

Authors:  R C Tait
Journal:  Thorax       Date:  2001-09       Impact factor: 9.139

2.  Value-of-information analysis to reduce decision uncertainty associated with the choice of thromboprophylaxis after total hip replacement in the Irish healthcare setting.

Authors:  Laura McCullagh; Cathal Walsh; Michael Barry
Journal:  Pharmacoeconomics       Date:  2012-10-01       Impact factor: 4.981

Review 3.  The post-thrombotic syndrome: the forgotten morbidity of deep venous thrombosis.

Authors:  Susan R Kahn
Journal:  J Thromb Thrombolysis       Date:  2006-02       Impact factor: 2.300

Review 4.  The postthrombotic syndrome.

Authors:  Raffaele Pesavento; Sabina Villalta; Paolo Prandoni
Journal:  Intern Emerg Med       Date:  2009-12-10       Impact factor: 3.397

Review 5.  Duration of anticoagulant therapy in pediatric venous thromboembolism: Current approaches and updates from randomized controlled trials.

Authors:  Cristina Tarango; Sam Schulman; Marisol Betensky; Neil A Goldenberg
Journal:  Expert Rev Hematol       Date:  2017-12-17       Impact factor: 2.929

6.  A Caprini Risk Score-Based Cost-Effectiveness Analysis of Enoxaparin for the Thromboprophylaxis of Patients After Nonorthopedic Surgery in a Chinese Healthcare Setting.

Authors:  Yun Bao; Gang Zhao; Shuli Qu; Tengbin Xiong; Xingxing Yao; Bin Wu
Journal:  Clin Drug Investig       Date:  2020-02       Impact factor: 2.859

7.  Cost Effectiveness of Apixaban and Enoxaparin for the Prevention of Venous Thromboembolism After Total Knee Replacement in China.

Authors:  Xiaoyu Yan; Xiaohua Gu; Lei Zhou; Houweng Lin; Bin Wu
Journal:  Clin Drug Investig       Date:  2016-12       Impact factor: 2.859

8.  New Oral Anticoagulants for Thromboprophylaxis in Patients with Cancer Receiving Chemotherapy: An Economic Evaluation in a Chinese Setting.

Authors:  Jiangyang Du; Bin Wu
Journal:  Clin Drug Investig       Date:  2020-07       Impact factor: 2.859

9.  Cost-effectiveness of additional catheter-directed thrombolysis for deep vein thrombosis.

Authors:  T Enden; S Resch; C White; H S Wik; N E Kløw; P M Sandset
Journal:  J Thromb Haemost       Date:  2013-06       Impact factor: 5.824

10.  An economic evaluation of venous thromboembolism prophylaxis strategies in critically ill trauma patients at risk of bleeding.

Authors:  T Carter Chiasson; Braden J Manns; Henry Thomas Stelfox
Journal:  PLoS Med       Date:  2009-06-23       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.